Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ejca.2013.04.019 http://scihub22266oqcxt.onion/10.1016/j.ejca.2013.04.019 C4666006!4666006 !23726267     free     free     free Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 225.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 259.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\23726267 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Eur+J+Cancer 2013 ; 49 (13 ): 2841-50 Nephropedia Template TP {{tp|p=23726267 |t=2013. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma |pdf=|usr=}}{{23726267 }} gab.com Text Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma JO: Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=23726267 #FOAvip BACKGROUND: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, with a long half-life. Tivozanib has demonstrated clinical activity and acceptable tolerability in renal cell carcinoma (RCC). This phase Ib study determined the recommended phase II dose (RP2D) and evaluated the safety and clinical activity of tivozanib plus temsirolimus, a mammalian target of rapamycin inhibitor. PATIENTS AND METHODS: Patients with advanced RCC were administered open-label tivozanib 0.5, 1.0 or 1.5mg/d orally (3 weeks on/1 week off) and temsirolimus 15 or 25 mg/week intravenously in a 3+3 dose-escalation design and subsequent expansion cohort. RESULTS: Of 27 patients treated, 20 patients had received ? 1 prior VEGF-targeted therapy. No dose-limiting toxicities occurred; the RP2D was determined to be tivozanib 1.5mg/d plus temsirolimus 25mg/week. Combination of tivozanib plus temsirolimus demonstrated acceptable tolerability and suggested no synergistic toxicity. The most common grade ? 3 adverse events were fatigue and thrombocytopenia (15% each). One patient each required dose reduction of tivozanib or temsirolimus due to an adverse event. Confirmed partial responses and stable disease were achieved at 23% and 68%, respectively. Pharmacokinetic analyses may suggest lack of an interaction between tivozanib and temsirolimus. CONCLUSIONS: In this small phase Ib study, tivozanib and temsirolimus were safely combined at the fully recommended dose and schedule of both agents. The observed clinical activity and manageable toxicity profile of this combination warrant further exploration in patients with RCC. Twit Text FOAVip Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma ????Eur J Cancer http://www.kidney.de/pget.php?&tw=1&pmid=23726267 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=23726267 #FOAvip English Wikipedia <ref>{{Cite pmid|23726267 }}</ref> Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma #MMPMID23726267 Fishman MN ; Srinivas S ; Hauke RJ ; Amato RJ ; Esteves B ; Cotreau MM ; Strahs AL ; Slichenmyer WJ ; Bhargava P ; Kabbinavar FF Eur J Cancer 2013[Sep]; 49 (13 ): 2841-50 PMID23726267 show ga BACKGROUND: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, with a long half-life. Tivozanib has demonstrated clinical activity and acceptable tolerability in renal cell carcinoma (RCC). This phase Ib study determined the recommended phase II dose (RP2D) and evaluated the safety and clinical activity of tivozanib plus temsirolimus, a mammalian target of rapamycin inhibitor. PATIENTS AND METHODS: Patients with advanced RCC were administered open-label tivozanib 0.5, 1.0 or 1.5mg/d orally (3 weeks on/1 week off) and temsirolimus 15 or 25 mg/week intravenously in a 3+3 dose-escalation design and subsequent expansion cohort. RESULTS: Of 27 patients treated, 20 patients had received ? 1 prior VEGF-targeted therapy. No dose-limiting toxicities occurred; the RP2D was determined to be tivozanib 1.5mg/d plus temsirolimus 25mg/week. Combination of tivozanib plus temsirolimus demonstrated acceptable tolerability and suggested no synergistic toxicity. The most common grade ? 3 adverse events were fatigue and thrombocytopenia (15% each). One patient each required dose reduction of tivozanib or temsirolimus due to an adverse event. Confirmed partial responses and stable disease were achieved at 23% and 68%, respectively. Pharmacokinetic analyses may suggest lack of an interaction between tivozanib and temsirolimus. CONCLUSIONS: In this small phase Ib study, tivozanib and temsirolimus were safely combined at the fully recommended dose and schedule of both agents. The observed clinical activity and manageable toxicity profile of this combination warrant further exploration in patients with RCC. |Administration, Intravenous [MESH] |Administration, Oral [MESH] |Adult [MESH] |Aged [MESH] |Angiogenesis Inhibitors/administration & dosage [MESH] |Antineoplastic Combined Chemotherapy Protocols/adverse effects/pharmacokinetics/*therapeutic use [MESH] |Carcinoma, Renal Cell/*drug therapy/enzymology/mortality [MESH] |Drug Administration Schedule [MESH] |Female [MESH] |Humans [MESH] |Kaplan-Meier Estimate [MESH] |Kidney Neoplasms/*drug therapy/enzymology/mortality [MESH] |Male [MESH] |Maximum Tolerated Dose [MESH] |Middle Aged [MESH] |Phenylurea Compounds/administration & dosage [MESH] |Protein Kinase Inhibitors/administration & dosage [MESH] |Quinolines/administration & dosage [MESH] |Sirolimus/administration & dosage/analogs & derivatives [MESH] |TOR Serine-Threonine Kinases/antagonists & inhibitors/metabolism [MESH] |Time Factors [MESH]Phase Ib study of tivozanib (AV-951) in combination with temsirolimus (epmc).pdf DeepDyve Pubget Overpricing